Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 18/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 14/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660301 | 0.95 | AAK1 (0.42) | AAK1NTRK1NTRK3NTRK2JAK2 | |
| SCHEMBL23931670 | 0.89 | NTRK1 (0.38) | NTRK1JAK2GPBAR1 | |
| SCHEMBL29660254 | 0.87 | AAK1 (0.56) | AAK1JAK2GPBAR1 | |
| SCHEMBL29660305 | 0.86 | AAK1 (0.44) | AAK1NTRK1NTRK3NTRK2JAK2 | |
| SCHEMBL29660252 | 0.85 | AAK1 (0.42) | AAK1NTRK1NTRK3NTRK2GPBAR1 | |
| SCHEMBL23931614 | 0.84 | NTRK1 (0.39) | NTRK1NTRK3NTRK2JAK2GPBAR1 | |
| SCHEMBL29660313 | 0.81 | AAK1 (0.58) | AAK1NTRK1NTRK3NTRK2JAK2 | |
| SCHEMBL23931673 | 0.81 | NTRK1 (0.40) | NTRK1JAK2GPBAR1 | |
| SCHEMBL29660281 | 0.79 | AAK1 (0.43) | AAK1NTRK1NTRK3NTRK2GPBAR1 | |
| SCHEMBL23931615 | 0.79 | NTRK1 (0.41) | NTRK1JAK2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | LEXICON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | OXFORD FINANCE LLC | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | IRAK1, SARS1, IRAK2 | AAK1 4/4885NTRK1 1718/4885NTRK3 1844/4885 |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | IRAK1, SARS1, IRAK2 | AAK1 4/4885NTRK1 1718/4885NTRK3 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.